Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Inventory (2022 - 2026)

TriSalus Life Sciences has reported Inventory over the past 5 years, most recently at $3.8 million for Q1 2026.

  • For Q1 2026, Inventory fell 9.23% year-over-year to $3.8 million; the TTM value through Mar 2026 reached $3.8 million, down 9.23%, while the annual FY2025 figure was $3.1 million, 23.99% down from the prior year.
  • Inventory for Q1 2026 was $3.8 million at TriSalus Life Sciences, up from $3.1 million in the prior quarter.
  • Over five years, Inventory peaked at $4.2 million in Q1 2025 and troughed at $1.5 million in Q4 2022.
  • A 5-year average of $3.2 million and a median of $3.4 million in 2024 define the central range for Inventory.
  • Biggest five-year swings in Inventory: surged 145.49% in 2024 and later decreased 23.99% in 2025.
  • Year by year, Inventory stood at $1.5 million in 2022, then surged by 73.01% to $2.5 million in 2023, then skyrocketed by 59.06% to $4.0 million in 2024, then decreased by 23.99% to $3.1 million in 2025, then grew by 22.78% to $3.8 million in 2026.
  • Business Quant data shows Inventory for TLSI at $3.8 million in Q1 2026, $3.1 million in Q4 2025, and $3.3 million in Q3 2025.